Endothelial cell malignancies: new insights from the laboratory and clinic

Abstract Endothelial cell malignancies are rare in the Western world and range from intermediate grade hemangioendothelioma to Kaposi sarcoma to aggressive high-grade angiosarcoma that metastasize early and have a high rate of mortality. These malignancies are associated with dysregulation of normal...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Michael J. Wagner, Vinod Ravi, David G. Menter, Anil K. Sood
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/156ffe4469384bac8a0ce44904514696
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:156ffe4469384bac8a0ce44904514696
record_format	dspace
spelling	oai:doaj.org-article:156ffe4469384bac8a0ce449045146962021-12-02T14:18:30ZEndothelial cell malignancies: new insights from the laboratory and clinic10.1038/s41698-017-0013-22397-768Xhttps://doaj.org/article/156ffe4469384bac8a0ce449045146962017-04-01T00:00:00Zhttps://doi.org/10.1038/s41698-017-0013-2https://doaj.org/toc/2397-768XAbstract Endothelial cell malignancies are rare in the Western world and range from intermediate grade hemangioendothelioma to Kaposi sarcoma to aggressive high-grade angiosarcoma that metastasize early and have a high rate of mortality. These malignancies are associated with dysregulation of normal endothelial cell signaling pathways, including the vascular endothelial growth factor, angiopoietin, and Notch pathways. Discoveries over the past two decades related to mechanisms of angiogenesis have led to the development of many drugs that intuitively would be promising therapeutic candidates for these endothelial-derived tumors. However, clinical efficacy of such drugs has been limited. New insights into the mechanisms that lead to dysregulated angiogenesis such as mutation or amplification in known angiogenesis related genes, viral infection, and chromosomal translocations have improved our understanding of the pathogenesis of endothelial malignancies and how they evade anti-angiogenesis drugs. In this review, we describe the major molecular alterations in endothelial cell malignancies and consider emerging opportunities for improving therapeutic efficacy against these rare but deadly tumors.Michael J. WagnerVinod RaviDavid G. MenterAnil K. SoodNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Precision Oncology, Vol 1, Iss 1, Pp 1-13 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Michael J. Wagner Vinod Ravi David G. Menter Anil K. Sood Endothelial cell malignancies: new insights from the laboratory and clinic
description	Abstract Endothelial cell malignancies are rare in the Western world and range from intermediate grade hemangioendothelioma to Kaposi sarcoma to aggressive high-grade angiosarcoma that metastasize early and have a high rate of mortality. These malignancies are associated with dysregulation of normal endothelial cell signaling pathways, including the vascular endothelial growth factor, angiopoietin, and Notch pathways. Discoveries over the past two decades related to mechanisms of angiogenesis have led to the development of many drugs that intuitively would be promising therapeutic candidates for these endothelial-derived tumors. However, clinical efficacy of such drugs has been limited. New insights into the mechanisms that lead to dysregulated angiogenesis such as mutation or amplification in known angiogenesis related genes, viral infection, and chromosomal translocations have improved our understanding of the pathogenesis of endothelial malignancies and how they evade anti-angiogenesis drugs. In this review, we describe the major molecular alterations in endothelial cell malignancies and consider emerging opportunities for improving therapeutic efficacy against these rare but deadly tumors.
format	article
author	Michael J. Wagner Vinod Ravi David G. Menter Anil K. Sood
author_facet	Michael J. Wagner Vinod Ravi David G. Menter Anil K. Sood
author_sort	Michael J. Wagner
title	Endothelial cell malignancies: new insights from the laboratory and clinic
title_short	Endothelial cell malignancies: new insights from the laboratory and clinic
title_full	Endothelial cell malignancies: new insights from the laboratory and clinic
title_fullStr	Endothelial cell malignancies: new insights from the laboratory and clinic
title_full_unstemmed	Endothelial cell malignancies: new insights from the laboratory and clinic
title_sort	endothelial cell malignancies: new insights from the laboratory and clinic
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/156ffe4469384bac8a0ce44904514696
work_keys_str_mv	AT michaeljwagner endothelialcellmalignanciesnewinsightsfromthelaboratoryandclinic AT vinodravi endothelialcellmalignanciesnewinsightsfromthelaboratoryandclinic AT davidgmenter endothelialcellmalignanciesnewinsightsfromthelaboratoryandclinic AT anilksood endothelialcellmalignanciesnewinsightsfromthelaboratoryandclinic
_version_	1718391590867697664

Endothelial cell malignancies: new insights from the laboratory and clinic

Ejemplares similares